References
Vitiello GAF, Amarante MK, Banin-Hirata BK, Campos CZ, de Oliveira KB, Losi-Guembarovski R, Watanabe MAE (2019) Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism in Brazilian breast cancer patients: association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05370-1
Yasri S, Wiwanitkit V (2019) Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-019-05414-6
Seijo ER, Song H, Lynch MA, Jennings R, Qong X, Lazaridis E, Muro-Cacho C, Weghorst CM, Muñoz-Antonia T (2001) Identification of genetic alterations in the TGFβ type II receptor gene promoter. Mutat Res/Fundam Mol Mech Mutagen 483(1–2):19–26. https://doi.org/10.1016/s0027-5107(01)00217-2
Choe B-K, Kim SK, Park HJ, Park H-K, Kwon KH, Lim SH, Yim S-V (2012) Polymorphisms of TGFBR2 contribute to the progression of papillary thyroid carcinoma. Mol Cell Toxicol 8(1):1–8. https://doi.org/10.1007/s13273-012-0001-0
Huang Y-S, Zhong Y, Yu L, Wang L (2014) Association between the TGFBR2 G-875A polymorphism and cancer risk: evidence from a meta-analysis. Asian Pac J Cancer Prev 15(20):8705–8708. https://doi.org/10.7314/apjcp.2014.15.20.8705
Zhang MEI, Guo L-L, Cheng Z, Liu R-Y, Lu Y, Qian Q, Lei ZHE, Zhang H-T (2011) A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER + , PR + , ER + PR + and HER2 − expression in women. Oncol Lett 2(4):653–658. https://doi.org/10.3892/ol.2011.312
Kim SJ, Im YH, Markowitz SD, Bang YJ (2000) Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 11(1–2):159–168
Sato M, Kadota M, Tang B, Yang HH, Yang YA, Shan M, Weng J, Welsh MA, Flanders KC, Nagano Y, Michalowski AM, Clifford RJ, Lee MP, Wakefield LM (2014) An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-beta in human breast cancer. Breast Cancer Res: BCR 16(3):R57. https://doi.org/10.1186/bcr3668
Pang MF, Georgoudaki AM, Lambut L, Johansson J, Tabor V, Hagikura K, Jin Y, Jansson M, Alexander JS, Nelson CM, Jakobsson L, Betsholtz C, Sund M, Karlsson MC, Fuxe J (2016) TGF-beta1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR9/CCL21-mediated chemotaxis. Oncogene 35(6):748–760. https://doi.org/10.1038/onc.2015.133
Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL (2011) TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Can Res 71(13):4707–4719. https://doi.org/10.1158/0008-5472.CAN-10-4554
Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, Stanford J, Cook RS, Arteaga CL (2013) TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Investig 123(3):1348–1358. https://doi.org/10.1172/JCI65416
Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K (2013) miR-655 is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS ONE 8(5):e62757. https://doi.org/10.1371/journal.pone.0062757
Wang J, Liang S, Duan X (2019) Molecular mechanism of miR-153 inhibiting migration, invasion and epithelial-mesenchymal transition of breast cancer by regulating transforming growth factor beta (TGF-beta) signaling pathway. J Cell Biochem 120(6):9539–9546. https://doi.org/10.1002/jcb.28230
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
This article does not contain any studies with human participants performed by any of the authors and requires no informed consent provision.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Vitiello, G.A.F., Amarante, M.K., Banin-Hirata, B.K. et al. Authors’ reply to the comment “Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism”. Breast Cancer Res Treat 179, 519–520 (2020). https://doi.org/10.1007/s10549-019-05452-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-019-05452-0